Brazil tests homegrown mRNA booster against COVID-19
NCT ID NCT07640308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new mRNA COVID-19 booster vaccine made by Bio-Manguinhos/Fiocruz. About 90 healthy adults aged 18-59 will receive one of three doses (25, 50, or 100 micrograms) to check safety and immune response. The study is not yet recruiting and will monitor participants for up to 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bio-Manguinhos/Fiocruz COVID-19 mRNA vaccine
- What this could lead to
- If successful, this could provide a new booster option to strengthen protection against COVID-19.
- What could go wrong
- This is a very early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. The vaccine may cause side effects or fail to boost immunity as expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ACUTE RESPIRATORY SYNDROME (SARS-COV-2 VIRUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.